Nephraegis Therapeutics

Executive Summary

Nephraegis Therapeutics is a private, San Diego-based biotechnology company advancing novel small molecule therapies for acute kidney injury (AKI) and chronic kidney disease (CKD). Founded in 2018, the company targets cellular energetics and metabolism pathways to promote kidney repair and regeneration, addressing a critical unmet need in nephrology where treatment options remain limited. Nephraegis is currently in the preclinical stage, focusing on lead optimization and IND-enabling studies. Their differentiated approach aims to modulate mitochondrial function and energy homeostasis, potentially enabling kidney tissue recovery and slowing disease progression. Given the high prevalence of AKI and CKD, any successful therapeutic could address multi-billion-dollar markets. However, as a preclinical private company with no disclosed funding rounds or partnerships, Nephraegis faces significant development risk and capital requirements to move toward clinical trials. The company's near-term progress hinges on completing validation studies and securing financing.

Upcoming Catalysts (preview)

• Q3 2026IND-enabling studies completion and regulatory submission for lead program30% success
• Q3 2026Series A or B financing round to fund clinical development40% success
• Q3 2026Presentation of preclinical efficacy data at a major nephrology conference50% success